病毒灭活市场规模、份额及成长分析（依方法、产品、应用、最终用户及地区划分）－2026-2033年产业预测

全球病毒灭活市场规模预计在 2024 年达到 6.7646 亿美元，从 2025 年的 7.5966 亿美元增长到 2033 年的 19.2159 亿美元，在预测期（2026-2033 年）内复合年增长率为 12.3%。

全球病毒灭活市场预计将迎来显着成长，这主要得益于製药、生物技术和医疗保健产业对高效能病毒去除解决方案日益增长的需求。随着生物製药产量的不断提高，病毒灭活对于去除生物製药、疫苗和治疗产品中的病原体至关重要。市场趋势凸显了遵守严格监管标准的重要性，迫使企业实施稳健的病毒灭活方法以降低污染风险。生物製造中一次性技术的日益普及提高了生产效率，降低了交叉污染的可能性，并符合病毒风险缓解策略。此外，製药和生技产业外包模式的兴起也提升了受託研究机构（CRO）在病毒灭活服务领域的作用，为市场创新与合作创造了机会。

全球病毒灭活市场驱动因素

生物製药研发，尤其是在单株抗体、基因治疗和个人化医疗等领域的日益重视，显着推动了对高效能病毒灭活技术的需求。随着先进生物製药和治疗方法的不断涌现，确保病毒安全性对于维护这些创新治疗方法的完整性和安全性至关重要。严格的监管合规要求以及对提供高品质、无污染生物製药的承诺，进一步推动了这项需求的成长。因此，在全球市场格局中，成功的病毒灭活变得愈发重要。

限制全球病毒灭活市场发展的因素

製药和生物技术产业复杂多变的法规环境为病毒灭活市场带来了巨大挑战。企业面临遵守监管机构复杂要求的艰鉅任务，这些要求往往繁琐且耗时。为了确保病毒灭活方法的有效性，企业必须进行广泛的检验研究并保存详尽的文件。这个严格的流程通常会导致营运成本增加和时间延长，从而阻碍市场整体效率和发展。因此，如何应对这些监管障碍仍是病毒灭活领域企业面临的一大阻碍因素。

全球病毒灭活市场趋势

随着生物製药生产的重要性日益凸显，全球病毒灭活市场正经历显着成长。这一快速增长主要得益于复杂生物製药（包括单株抗体、基因疗法和细胞疗法）的兴起，这些製剂需要严格的病毒安全通讯协定。随着业界不断采用创新治疗方法，强化病毒灭活策略对于确保患者安全和产品完整性至关重要。这一趋势凸显了生物製药领域对先进技术和严格监管合规的迫切需求，最终将推动市场扩张，并在不断变化的治疗需求面前建立更具韧性的供应链。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球病毒灭活市场规模（依方法及复合年增长率划分）（2026-2033 年）

• 溶剂清洁剂法
• 巴氏杀菌法
• 其他病毒灭活方法

全球病毒灭活市场规模（按产品和复合年增长率划分）（2026-2033 年）

• 试剂盒和试剂
• 服务
• 病毒灭活系统及配件

全球病毒灭活市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 血液和血液製品
• 细胞和基因疗法产品
• 干细胞产品
• 组织和组织产品
• 疫苗和治疗

全球病毒灭活市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 製药和生物技术公司
• 合约研究机构
• 学术研究机构
• 其他最终用户

全球病毒灭活市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Merck KGaA（Germany）
• Sartorius AG（Germany）
• Charles River Laboratories International, Inc.（United States）
• Parker Hannifin Corporation（United States）
• Thermo Fisher Scientific Inc.（United States）
• Bio-Rad Laboratories, Inc.（United States）
• Mettler-Toledo International Inc.（United States）
• SGS SA（Switzerland）
• WuXi AppTec Co., Ltd.（China）
• Lonza Group AG（Switzerland）
• Pfizer Inc.（United States）
• GE HealthCare Technologies Inc.（United States）
• Danaher Corporation（United States）
• Cerus Corporation（United States）
• Terumo BCT, Inc.（United States）
• Eurofins Scientific SE（Luxembourg）
• Macopharma SA（France）
• Kedrion SpA（Italy）
• Rad Source Technologies, Inc.（United States）

结论与建议

Global Viral Inactivation Market size was valued at USD 676.46 Million in 2024 and is poised to grow from USD 759.66 Million in 2025 to USD 1921.59 Million by 2033, growing at a CAGR of 12.3% during the forecast period (2026-2033).

The global viral inactivation market is set to experience significant growth, fueled by the increasing demand for effective viral clearance solutions across pharmaceuticals, biotechnology, and healthcare sectors. As biopharmaceutical production rises, the necessity for viral inactivation becomes essential in eliminating infectious agents from biological products, vaccines, and therapeutic formulations. Market trends highlight the importance of adhering to strict regulatory standards, compelling companies to implement robust viral inactivation methods to reduce contamination risks. The growing use of single-use technologies in biomanufacturing enhances production efficiency and lowers cross-contamination potential, aligning with viral risk reduction strategies. Additionally, the shift towards outsourcing in the pharmaceutical and biotechnology industries elevates the role of contract research organizations in providing viral inactivation services, creating opportunities for innovation and collaboration within the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Viral Inactivation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Viral Inactivation Market Segments Analysis

Global Viral Inactivation Market is segmented by Method, Product, Application, End User and region. Based on Method, the market is segmented into Solvent Detergent Method, Pasteurization and Other Viral Inactivation Method. Based on Product, the market is segmented into Kits and Reagents, Services and Viral Inactivation Systems and Accessories. Based on Application, the market is segmented into Blood & Blood Products, Cellular & Gene Therapy Products, Stem Cell Products, Tissue & Tissue Products and Vaccines and Therapeutics. Based on End User, the market is segmented into Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic Research Institutes and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Viral Inactivation Market

The increasing focus on biopharmaceutical research and development, especially within the realms of monoclonal antibodies, gene therapies, and personalized medicine, is significantly fueling the demand for effective viral inactivation techniques. As the creation of sophisticated biologics and advanced therapies continues to expand, ensuring viral safety is essential for preserving the integrity and safety of these innovative treatments. This growing necessity is further driven by the imperative for stringent regulatory adherence and a commitment to delivering high-quality, contaminant-free biopharmaceutical products. Consequently, the emphasis on successful viral inactivation is becoming ever more critical in the global market landscape.

Restraints in the Global Viral Inactivation Market

The complex and constantly changing regulatory environment in the pharmaceutical and biotechnology industries poses significant challenges for the viral inactivation market. Companies face the daunting task of complying with intricate requirements dictated by regulatory bodies, which can be both demanding and lengthy. To ensure that their viral inactivation methods are effective, businesses must undertake extensive validation studies and maintain meticulous documentation. This rigorous process often results in higher operational costs and extended timelines, hindering overall efficiency and progress within the market. Consequently, navigating these regulatory hurdles remains a critical restraint for companies working in the viral inactivation space.

Market Trends of the Global Viral Inactivation Market

The Global Viral Inactivation market is experiencing significant growth due to the escalating prominence of biopharmaceutical manufacturing. This surge is fueled by the rise in complex biologics such as monoclonal antibodies, gene therapies, and cell-based therapies, which require rigorous viral safety protocols. As the industry embraces innovative treatment modalities, enhanced viral inactivation strategies have become critical to ensure patient safety and product integrity. This trend highlights the necessity for advanced technologies and robust regulatory compliance in the biopharmaceutical sector, ultimately driving market expansion and fostering a more resilient supply chain in the face of evolving therapeutic demands.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Viral Inactivation Market Size by Method & CAGR (2026-2033)

• Market Overview
• Solvent Detergent Method
• Pasteurization
• Other Viral Inactivation Method

Global Viral Inactivation Market Size by Product & CAGR (2026-2033)

• Market Overview
• Kits and Reagents
• Services
• Viral Inactivation Systems and Accessories

Global Viral Inactivation Market Size by Application & CAGR (2026-2033)

• Market Overview
• Blood & Blood Products
• Cellular & Gene Therapy Products
• Stem Cell Products
• Tissue & Tissue Products
• Vaccines and Therapeutics

Global Viral Inactivation Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutes
• Other End Users

Global Viral Inactivation Market Size & CAGR (2026-2033)

• North America (Method, Product, Application, End User)
  • US
  • Canada
• Europe (Method, Product, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Method, Product, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Method, Product, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Method, Product, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parker Hannifin Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mettler-Toledo International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGS SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE HealthCare Technologies Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cerus Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo BCT, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific SE (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macopharma SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rad Source Technologies, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations